Target detail
ACVR1
activin A receptor type 1
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: activin A receptor type 1
Aliases: ACVR1, activin A receptor type 1
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000115170
Index freshness: last_synced_at 2026-05-15T18:13:22.268+00:00 · updated 2026-05-15T18:13:22.648213+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ACVR1. Empty groups mean no matching rows — not a claim about biology or clinical use.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
- ChEMBLLive when indexed
Drug–target and related enrichment rows when operators run enrich:chembl (server/CLI only).
- CANTI signal builderLive when indexed
Deterministic repurposing-signal rows produced by the in-repo signal builder when operators run the build pipeline.
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
CHEMBL511337
chembl511337
CHEMBL2000078
chembl2000078
CHEMBL1971223
chembl1971223
CHEMBL478649
chembl478649
CHEMBL2002992
chembl2002992
PELITINIB
chembl607707
CHEMBL1825138
chembl1825138
CHEMBL1949855
chembl1949855
SNS-314
chembl482767
CHEMBL2001613
chembl2001613
CHEMBL3341945
chembl3341945
CHEMBL1980246
chembl1980246
CHEMBL1978371
chembl1978371
CHEMBL1969156
chembl1969156
CHEMBL1996345
chembl1996345
PAZOPANIB
chembl477772
AST-487
chembl574738
CHEMBL1983111
chembl1983111
STAUROSPORINE
chembl388978
CHEMBL516312
chembl516312
CHEMBL1968705
chembl1968705
CHEMBL1996176
chembl1996176
CHEMBL526901
chembl526901
CHEMBL3341792
chembl3341792
SORAFENIB
chembl1336
RG-1530
chembl1980391
CHEMBL1978267
chembl1978267
CHEMBL2000568
chembl2000568
CHEMBL1978271
chembl1978271
CHEMBL3394112
chembl3394112
CHEMBL1997924
chembl1997924
CHEMBL1995211
chembl1995211
CHEMBL1992073
chembl1992073
GW632580X
chembl261849
VANDETANIB
chembl24828
CHEMBL1993877
chembl1993877
CHEMBL3341944
chembl3341944
CHEMBL3341948
chembl3341948
CHEMBL2002736
chembl2002736
CHEMBL1992937
chembl1992937
CRIZOTINIB
chembl601719
CHEMBL2006674
chembl2006674
CHEMBL1964275
chembl1964275
CHEMBL450519
chembl450519
CHEMBL1980376
chembl1980376
CHEMBL1988076
chembl1988076
CHEMBL1986143
chembl1986143
CHEMBL1985042
chembl1985042
CHEMBL1822054
chembl1822054
CHEMBL1796257
chembl1796257
CHEMBL2007479
chembl2007479
CHEMBL1994977
chembl1994977
CHEMBL1991734
chembl1991734
ENZASTAURIN
chembl300138
AFATINIB
chembl1173655
CHEMBL1964441
chembl1964441
CHEMBL1968868
chembl1968868
CHEMBL2001641
chembl2001641
CHEMBL1988141
chembl1988141
CHEMBL1965387
chembl1965387
CHEMBL242865
chembl242865
CHEMBL1999414
chembl1999414
CHEMBL1968130
chembl1968130
DIBOTERMIN ALFA
chembl2109171
CHEMBL1983348
chembl1983348
FEDRATINIB
chembl1287853
CHEMBL1992581
chembl1992581
CHEMBL1973016
chembl1973016
CHEMBL1982711
chembl1982711
VACTOSERTIB
chembl3260567
CHEMBL2002586
chembl2002586
CHEMBL1975212
chembl1975212
CHEMBL225519
chembl225519
PHA-665752
chembl450786
CHEMBL1997193
chembl1997193
CHEMBL1998470
chembl1998470
CHEMBL3341951
chembl3341951
PI-103
chembl573339
CHEMBL1986684
chembl1986684
CHEMBL257167
chembl257167
CHEMBL2002480
chembl2002480
ILORASERTIB
chembl1980297
CHEMBL1977138
chembl1977138
CHEMBL482538
chembl482538
CHEMBL3774448
chembl3774448
CHEMBL1421720
chembl1421720
CHEMBL1976376
chembl1976376
CHEMBL1983923
chembl1983923
LESTAURTINIB
chembl603469
SB-202190
chembl278041
CHEMBL3341791
chembl3341791
CHEMBL1163518
chembl1163518
CHEMBL1983884
chembl1983884
CHEMBL1164180
chembl1164180
CHEMBL1988581
chembl1988581
BOSUTINIB
chembl288441
CHEMBL406845
chembl406845
CHEMBL1973013
chembl1973013
PICTILISIB
chembl521851
DORSOMORPHIN
chembl478629
CHEMBL3341789
chembl3341789
NILOTINIB
chembl255863
CHEMBL1989043
chembl1989043
CHEMBL1995765
chembl1995765
MOTESANIB
chembl572881
CHEMBL1983640
chembl1983640
CHEMBL2425654
chembl2425654
CHEMBL2385590
chembl2385590
CENISERTIB
chembl1967878
CHEMBL1982660
chembl1982660
CHEMBL1973793
chembl1973793
CHEMBL3758502
chembl3758502
CHEMBL2002105
chembl2002105
CHEMBL2001923
chembl2001923
CHEMBL2001987
chembl2001987
CHEMBL1964382
chembl1964382
CHEMBL1974617
chembl1974617
OSI-632
chembl253969
CHEMBL3394105
chembl3394105
CHEMBL1967252
chembl1967252
CHEMBL3341942
chembl3341942
CHEMBL1988437
chembl1988437
CHEMBL1990254
chembl1990254
CHEMBL1164265
chembl1164265
CHEMBL2005478
chembl2005478
CHEMBL1908395
chembl1908395
CHEMBL1975121
chembl1975121
CHEMBL1997041
chembl1997041
CHEMBL1975927
chembl1975927
CHEMBL1979690
chembl1979690
CHEMBL1988805
chembl1988805
CHEMBL1870106
chembl1870106
CHEMBL1991078
chembl1991078
CHEMBL1971132
chembl1971132
CHEMBL3628627
chembl3628627
EPTOTERMIN ALFA
chembl2108594
CHEMBL1164181
chembl1164181
CHEMBL3341952
chembl3341952
CHEMBL1994724
chembl1994724
CHEMBL1981047
chembl1981047
CHEMBL3394118
chembl3394118
CHEMBL2425646
chembl2425646
HESPERADIN
chembl514409
PALBOCICLIB
chembl189963
CHEMBL1978166
chembl1978166
TG100-115
chembl230011
CHEMBL525191
chembl525191
CHEMBL86755
chembl86755
CHEMBL408019
chembl408019
CHEMBL1994318
chembl1994318
CHEMBL1978562
chembl1978562
CHEMBL331465
chembl331465
RUBOXISTAURIN
chembl91829
CHEMBL3215582
chembl3215582
CHEMBL1980995
chembl1980995
CHEMBL1984760
chembl1984760
CHEMBL1973516
chembl1973516
CHEMBL1978167
chembl1978167
GSK-461364
chembl1908394
CHEMBL1975903
chembl1975903
CHEMBL1985681
chembl1985681
LINIFANIB
chembl223360
CHEMBL1965169
chembl1965169
CHEMBL1982413
chembl1982413
CHEMBL1171523
chembl1171523
CHEMBL2385596
chembl2385596
SU-014813
chembl1721885
CHEMBL1980671
chembl1980671
CHEMBL3341947
chembl3341947
CHEMBL422897
chembl422897
CHEMBL604483
chembl604483
CHEMBL1984038
chembl1984038
CHEMBL1974998
chembl1974998
CHEMBL1996510
chembl1996510
CHEMBL1995811
chembl1995811
CHEMBL1969483
chembl1969483
CHEMBL2006439
chembl2006439
CHEMBL2007375
chembl2007375
CHEMBL1994159
chembl1994159
CHEMBL2385579
chembl2385579
CHEMBL1984842
chembl1984842
CHEMBL1964948
chembl1964948
BRIVANIB
chembl377300
CHEMBL2001539
chembl2001539
CHEMBL2004118
chembl2004118
KW-2449
chembl1908397
CHEMBL249097
chembl249097
ENTRECTINIB
chembl1983268
CHEMBL1991008
chembl1991008
CHEMBL1967612
chembl1967612
CHEMBL1908396
chembl1908396
CHEMBL1996576
chembl1996576
CHEMBL1992371
chembl1992371
CHEMBL1978448
chembl1978448
CHEMBL1996837
chembl1996837
CHEMBL2402081
chembl2402081
CHEMBL1230714
chembl1230714
CHEMBL2005699
chembl2005699
CHEMBL1992125
chembl1992125
CHEMBL1993335
chembl1993335
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
No matching live evidence found
Populate clinical_trials via the registry enrichment flow; this panel matches the symbol token in titles, conditions, or interventions.
Repurposing signal rows for drugs linked to this target via drug_targets.
Repurposing research signal · AST-487 · v0.1
Deterministic research signal for AST-487. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubRepurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
Open signals hubStructured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
No ClinicalTrials.gov mirror rows mention this symbol in titles, conditions, or interventions (within the loaded window).
- chembl: 500
- canti_signal_builder: 5
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
Repurposing research signal · ALVOCIDIB · v0.1
Deterministic research signal for ALVOCIDIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · CANERTINIB · v0.1
Deterministic research signal for CANERTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BOSUTINIB · v0.1
Deterministic research signal for BOSUTINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · AST-487 · v0.1
Deterministic research signal for AST-487. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BMS-387032 · v0.1
Deterministic research signal for BMS-387032. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · AT-9283 · v0.1
Deterministic research signal for AT-9283. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hubRepurposing research signal · BAFETINIB · v0.1
Deterministic research signal for BAFETINIB. Aggregate template score 55 (not a clinical endpoint). Contributing canonical sources observed in this rollup: chembl, opentargets. No failed-repoDB or terminated-trial penalty lines fired for this rollup. Missing relative to the Phase 8A template: glioma/brain-tumor–scoped ClinicalTrials.gov disease–drug evidence; repoDB-style disease–drug labels. This row requires clinical/research review before any operational use — not care-planning guidance, dose planning, or outcome-benefit claims.
View signals hub